Ipamorelin and SLU-PP-332 Interaction: Compatible | Peptide Database

Turinabol increases muscular strength and power output without the water retention and significant body mass increases associated with aromatizing compounds. This makes it particularly suited for athletes competing in weight-class sports or those requiring a high strength-to-weight ratio. Through enhanced red blood cell production and improved creatine phosphate resynthesis, turinabol supports aerobic and anaerobic endurance. Athletes report improved recovery between training sessions and sustained performance during competition periods. The East German doping program selected turinabol specifically for speed and power athletes, including sprinters, swimmers, and throwers. The compound enhances neuromuscular efficiency and explosive power without the weight penalty of water retention. Turinabol promotes gradual, quality lean tissue gains during caloric surplus periods. While the rate of gain is slower than with aromatizing orals like Dianabol, the gains are predominantly lean tissue with minimal fat or water, and are generally more maintainable post-cycle. During cutting phases, turinabol supports nitrogen retention and anti-catabolic effects, helping preserve lean muscle tissue while in a caloric deficit. The absence of water retention means all visible changes reflect actual tissue composition.

Join others researching PP405 — share findings, ask questions, and learn from real experiences PP405 is an investigational topical drug developed by Pelage Pharmaceuticals for the treatment of androgenetic alopecia. Based on research conducted at UCLA, PP405 works through a fundamentally different mechanism than existing hair loss treatments: rather than blocking androgens like finasteride or promoting blood flow like minoxidil, it targets the metabolic dormancy of hair follicle stem cells directly. By inhibiting the mitochondrial pyruvate carrier (MPC1/MPC2), PP405 causes pyruvate accumulation in hair follicle stem cells, stimulating lactate dehydrogenase activity and triggering a metabolic shift that reactivates dormant follicles. Phase 2a clinical trial results showed increased hair count and thickness with a 0.05% gel formulation applied once daily. As of 2025, the drug has completed Phase 2a trials, with Phase 3 trials planned for 2026. PP405 is a dual inhibitor of the mitochondrial pyruvate carrier complex, targeting both the MPC1 and MPC2 subunits. Under normal conditions, the MPC transports pyruvate from the cytoplasm into the mitochondrial matrix, where it enters the tricarboxylic acid (TCA) cycle for oxidative metabolism. In hair follicle stem cells (HFSCs), this standard metabolic pathway is associated with quiescence and dormancy. By blocking MPC1/MPC2, PP405 prevents pyruvate from entering the mitochondria, causing it to accumulate in the cytoplasm. This pyruvate buildup stimulates lactate dehydrogenase (LDH) activity, which converts pyruvate to lactate, shifting the cell's metabolic profile toward aerobic glycolysis. This metabolic reprogramming mimics the signaling environment that naturally triggers HFSCs to exit quiescence and re-enter the cell cycle. The activated stem cells then initiate a new anagen (growth) phase in dormant hair follicles. Critically, this mechanism is entirely independent of the androgen/DHT pathway targeted by finasteride and dutasteride, and distinct from the vasodilatory effects of minoxidil, meaning PP405 could be effective regardless of a patient's androgen status.